Scientific Data (Sep 2023)

Cancer-specific association between Tau (MAPT) and cellular pathways, clinical outcome, and drug response

  • Maurizio Callari,
  • Martina Sola,
  • Claudia Magrin,
  • Andrea Rinaldi,
  • Marco Bolis,
  • Paolo Paganetti,
  • Luca Colnaghi,
  • Stéphanie Papin

DOI
https://doi.org/10.1038/s41597-023-02543-y
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Tau (MAPT) is a microtubule-associated protein causing common neurodegenerative diseases or rare inherited frontotemporal lobar degenerations. Emerging evidence for non-canonical functions of Tau in DNA repair and P53 regulation suggests its involvement in cancer. To bring new evidence for a relevant role of Tau in cancer, we carried out an in-silico pan-cancer analysis of MAPT transcriptomic profile in over 10000 clinical samples from 32 cancer types and over 1300 pre-clinical samples from 28 cancer types provided by the TCGA and the DEPMAP datasets respectively. MAPT expression associated with key cancer hallmarks including inflammation, proliferation, and epithelial to mesenchymal transition, showing cancer-specific patterns. In some cancer types, MAPT functional networks were affected by P53 mutational status. We identified new associations of MAPT with clinical outcomes and drug response in a context-specific manner. Overall, our findings indicate that the MAPT gene is a potential major player in multiple types of cancer. Importantly, the impact of Tau on cancer seems to be heavily influenced by the specific cellular environment.